GlassScriptPhysician profile
Samantha Capatina
NPI 1669056818
$1,368.66
in general payments reported to CMS, 2019-2025
15 companies · $68.62 in 2025
The $68.62 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.68 · 2022: $274 · 2023: $900 · 2024: $98.31 · 2025: $68.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $457.83 | 2022-2023 | Solitaire X, Linq II |
| Abbvie INC. | $144.02 | 2022-2025 | Botox |
| Ucb, INC. | $135.34 | 2022-2024 | Briviact |
| Novartis Pharmaceuticals Corporation | $108.71 | 2024-2025 | |
| Imperative Care, INC | $100.68 | 2023 | Zoom 88-T Large Distal Platform |
| Penumbra, INC. | $97.53 | 2023 | Penumbra System |
| Novo Nordisk INC | $94.09 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $51.12 | 2022 | |
| Allergan, INC. | $47.88 | 2022 | |
| Alexion Pharmaceuticals, INC. | $38.05 | 2023 | Soliris |
| Jazz Pharmaceuticals INC. | $25.52 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $21.22 | 2023 | Firdapse |
| Acadia Pharmaceuticals INC | $18.99 | 2023 | Nuplazid |
| Janssen Pharmaceuticals, INC | $15.46 | 2021 | |
| Boston Scientific Corporation | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Capatina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.